GH
Guardant Health, Inc. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 5,
"returned": 5,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "debb7ab9-8919-4634-9111-3479437a80df",
"title": "Market Today: Marathon Digital Surges, BP Expands EV Charging Network",
"description": "Market Overview Today, the stock market saw broad gains across major indices, with increases ranging from 0.3% to 0.9%. The S&P 500 notably broke past the 5,200",
"keywords": "GuruFocus, Article, News, GuruFocus Research, Ken Fisher, First Eagle Investment, EQIX, NRG, STE, EPAM, AAPL, MS, ARM",
"snippet": "Market Overview\n\nToday, the stock market saw broad gains across major indices, with increases ranging from 0.3% to 0.9%. The S&P 500 notably broke past the 5,20...",
"url": "https://www.gurufocus.com/news/2434031/market-today-marathon-digital-surges-bp-expands-ev-charging-network",
"image_url": "https://static.gurufocus.com/1732803573856661504.png",
"language": "en",
"published_at": "2024-05-09T22:32:58.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GH",
"name": "Guardant Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.574022,
"sentiment_score": 0.9042,
"highlights": [
{
"highlight": "<em>Guardant</em> <em>Health</em> (GH) raised its annual revenue guidance after a strong first quarter, driven by increased test volumes and favorable pricing dynamics. The company's enhanced financial outlook reflects its continued growth in the precision oncology market.",
"sentiment": 0.9042,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "48de60f6-6ce4-4d49-bac0-136515b047ab",
"title": "Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics",
"description": "Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
"keywords": "stock, stocks, investment, investment advice, investing, online trading, online investment, online stock trading, stock market, financial, financial planning, quote, quotes, stock quotes",
"snippet": "This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herei...",
"url": "https://www.zacks.com/stock/news/2271845/compared-to-estimates-guardant-health-gh-q1-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2271845",
"image_url": "https://staticx-tuner.zacks.com/images/default_article_images/default215.jpg",
"language": "en",
"published_at": "2024-05-09T22:30:09.000000Z",
"source": "zacks.com",
"relevance_score": null,
"entities": [
{
"symbol": "GH",
"name": "Guardant Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 60.290474,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Compared to Estimates, <em>Guardant</em> <em>Health</em> (GH) Q1 Earnings: A Look at Key Metrics",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "55b6a867-8167-490d-ad16-c74f85db276f",
"title": "Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates",
"description": "Guardant Health (GH) delivered earnings and revenue surprises of 36.11% and 11.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?",
"keywords": "stock, stocks, investment, investment advice, investing, online trading, online investment, online stock trading, stock market, financial, financial planning, quote, quotes, stock quotes",
"snippet": "This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herei...",
"url": "https://www.zacks.com/stock/news/2271812/guardant-health-gh-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2271812",
"image_url": "https://staticx-tuner.zacks.com/images/default_article_images/default351.jpg",
"language": "en",
"published_at": "2024-05-09T22:05:06.000000Z",
"source": "zacks.com",
"relevance_score": null,
"entities": [
{
"symbol": "GH",
"name": "Guardant Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 68.20767,
"sentiment_score": 0.25,
"highlights": [
{
"highlight": "<em>Guardant</em> <em>Health</em> (GH) Reports Q1 Loss, Tops Revenue Estimates",
"sentiment": 0.25,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "c86b9004-2776-4721-bcf6-64031ea31bdb",
"title": "Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance By Investing.com",
"description": "Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance",
"keywords": "",
"snippet": "Revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds\n\nPALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (N...",
"url": "https://www.investing.com/news/press-releases/guardant-health-reports-first-quarter-2024-financial-results-and-increases-2024-revenue-guidance-93CH-3432778",
"image_url": "https://i-invdn-com.investing.com/news/news_pile_69x52._800x533_L_1419494209.jpg",
"language": "en",
"published_at": "2024-05-09T20:16:11.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "GH",
"name": "Guardant Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 75.84659,
"sentiment_score": 0.100509,
"highlights": [
{
"highlight": "--(BUSINESS WIRE)--<em>Guardant</em> <em>Health</em>, <em>Inc</em>. (<em>Nasdaq</em>: <em>GH</em>), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2024.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Guardant</em> <em>Health</em> now expects full year 2024 non-GAAP gross margin excluding screening to be in the range of 61% to 63%, compared to the prior range of 60% to 62%.",
"sentiment": -0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Guardant</em> <em>Health</em> now expects free cash flow to be in the range of $(275) to $(285) million in 2024, an improvement compared to the prior range of $(320) to $(330) million.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "See disclosureor\n\nNon-GAAP Measures\n\n<em>Guardant</em> <em>Health</em> has presented in this release certain financial information in accordance with U.S.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Guardant</em> <em>Health</em>\n\n<em>Guardant</em> <em>Health</em> is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics.",
"sentiment": 0.8393,
"highlighted_in": "main_text"
},
{
"highlight": "The forward-looking statements in this press release are based on information available to <em>Guardant</em> <em>Health</em> as of the date hereof, and <em>Guardant</em> <em>Health</em> disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "See disclosureor\n\n<em>Guardant</em> <em>Health</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Health</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "See disclosureor\n\n<em>Guardant</em> <em>Health</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Health</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Guardant</em> <em>Health</em> Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "60108013-c168-4ab4-b2bd-90472fb65b8f",
"title": "Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update",
"description": "Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with...",
"keywords": "Nasdaq:BDTX, Black Diamond Therapeutics, Inc",
"snippet": "Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024\n\n\n\nEnrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non...",
"url": "https://www.globenewswire.com/news-release/2024/05/09/2878644/0/en/Black-Diamond-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155",
"language": "en",
"published_at": "2024-05-09T11:30:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "GH",
"name": "Guardant Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.292385,
"sentiment_score": -0.0772,
"highlights": [
{
"highlight": "The oral presentation titled “BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical and the C797S Resistance Mutation to Address the Evolved Landscape of EGFR Mutant NSCLC,” evaluated more than 235,000 sequenced cases of NSCLC sourced from <em>Guardant</em> <em>Health</em> (GuardantINFORM™) and Foundation Medicine (FoundationInsights™).",
"sentiment": -0.0772,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "GH",
"total_documents": 5,
"sentiment_avg": 0.23550180345773697
}
]
}
Other details
Exchange
- NASDAQ Stock Exchange
- equity
- Healthcare
- us